Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

The technological innovation is an expansion of the NOBIVAC NXT platform, and a breakthrough achievement against one of the ...

Biomedicines and its artificial intelligence platform to generate drugs for multiple undisclosed targets. Generate will receive $65 million up front, which includes an equity investment of $15 million ...

First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., ...

Factors related to sex and gender can affect therapy outcomes and should not be overlooked in clinical practice or research.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

Ben-Aharon declared financial interests with AstraZeneca, MSD and Merck (invited speaker), and Bristol Myers Squibb and ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

And when I look at KEYTRUDA back in 2019, internationally, we only had 12 indications. So over that time, the clinical development work and the regulatory teams at MSD have done a fantastic job. We're ...

Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...